TABLE OF CONTENTS
1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.3 OVERVIEW OF THE ASIA PACIFIC FLOW CYTOMETRY MARKET 38
1.4 LIMITATIONS 40
1.5 MARKETS COVERED 40
2 MARKET SEGMENTATION 43
2.1 MARKETS COVERED 43
2.2 GEOGRAPHICAL SCOPE 44
2.3 YEARS CONSIDERED FOR THE STUDY 45
2.4 CURRENCY AND PRICING 45
2.5 DBMR TRIPOD DATA VALIDATION MODEL 46
2.6 MULTIVARIATE MODELLING 49
2.7 PRODUCT SEGMENT LIFELINE CURVE 49
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.9 DBMR MARKET POSITION GRID 51
2.10 MARKET APPLICATION COVERAGE GRID 52
2.11 VENDOR SHARE ANALYSIS 53
2.12 SECONDARY SOURCES 54
2.13 ASSUMPTIONS 54
3 EXECUTIVE SUMMARY 55
4 PREMIUM INSIGHTS 58
4.1 PORTERS FIVE FORCES 59
4.2 PESTEL ANALYSIS 60
5 MARKET OVERVIEW 61
5.1 DRIVERS 63
5.1.1 RISING PREVALENCE OF CHRONIC DISEASES 63
5.1.2 INCREASING APPLICATION OF CYTOMETRY INSTRUMENTS 64
5.1.3 INCREASE IN USE OF FLOW CYTOMETRY IN DRUG DISCOVERY 65
5.1.4 GROWTH IN STEM CELL RESEARCH AND ACQUISITION OF RECOMBINATION OF DNA TECHNOLOGIES 67
5.2 RESTRAINTS 68
5.2.1 HIGH COST OF FLOW CYTOMETRY INSTRUMENTS 68
5.2.2 LIMITATIONS OF FLOW CYTOMETRY 69
5.2.3 LACK OF SKILLED PROFESSIONALS 70
5.3 OPPORTUNITIES 71
5.3.1 INCREASE IN ADOPTION OF FLOW CYTOMETRY TECHNIQUES IN RESEARCH AND ACADEMIA 71
5.3.2 DEVELOPMENT IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES 72
5.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 73
5.3.4 DEVELOPING A PIPELINE OF STEM CELL RESEARCH 74
5.4 CHALLENGES 74
5.4.1 DIFFICULTY IN THE DEVELOPMENT AND VALIDATION OF FLOW CYTOMETRY ASSAYS 74
5.4.2 COMPLEXITIES RELATED TO REAGENT DEVELOPMENT 75
6 ASIA PACIFIC FLOW CYTOMETRY MARKET, BY PRODUCT 77
6.1 OVERVIEW 78
6.2 REAGENTS AND CONSUMABLES 81
6.2.1 DYE 82
6.2.2 ANTIBODIES 82
6.2.3 BEADS 82
6.2.4 OTHERS 82
6.3 FLOW CYTOMETRY INSTRUMENTS 82
6.3.1 CELL ANALYZERS 83
6.3.1.1 CELL ANALYZERS, BY TYPE 84
6.3.1.1.1 IMAGING FLOW CYTOMETERS 84
6.3.1.1.2 NON-IMAGING FLOW CYTOMETERS 84
6.3.1.2 CELL ANALYZERS, BY MODALITY 84
6.3.1.2.1 BENCHTOP 84
6.3.1.2.2 STANDALONE 84
6.3.2 CELL SORTERS 85
6.3.2.1 BENCHTOP 85
6.3.2.2 STANDALONE 85
6.4 ACCESSORIES 85
6.4.1 FILTERS 86
6.4.2 DETECTORS 86
6.4.3 OTHERS 86
6.5 SERVICES 87
6.6 SOFTWARE 87
7 ASIA PACIFIC FLOW CYTOMETRY MARKET, BY TECHNOLOGY 89
7.1 OVERVIEW 90
7.2 CELL-BASED FLOW CYTOMETRY 94
7.3 BEAD-BASED FLOW CYTOMETRY 95
8 ASIA PACIFIC FLOW CYTOMETRY MARKET, BY APPLICATION 96
8.1 OVERVIEW 97
8.2 RESEARCH APPLICATIONS 101
8.2.1 CELL CYCLE ANALYSIS 102
8.2.2 CELL SORTING/SCREENING 102
8.2.3 CELL TRANSFECTION/VIABILITY 102
8.2.4 PHARMACEUTICAL AND BIOTECHNOLOGY 103
8.2.4.1 DRUG DISCOVERY 103
8.2.4.2 STEM CELL RESEARCH 103
8.2.4.3 IN VITRO TOXICITY TESTING 103
8.2.5 IMMUNOLOGY 103
8.2.6 APOPTOSIS 103
8.2.7 CELL COUNTING 103
8.2.8 OTHERS 103
8.3 CLINICAL APPLICATIONS 104
8.3.1 HAEMATOLOGY 105
8.3.2 CANCER 105
8.3.3 IMMUNODEFICIENCY DISEASES 105
8.3.4 ORGAN TRANSPLANTATION 105
8.3.5 OTHER CLINICAL APPLICATION 105
8.4 INDUSTRIAL APPLICATIONS 105
9 ASIA PACIFIC FLOW CYTOMETRY MARKET, BY END USER 107
9.1 OVERVIEW 108
9.2 PHARMACEUTICALS & BIOTECHNOLOGY COMPANIES 111
9.3 ACADEMIC & RESEARCH INSTITUTES 112
9.4 HOSPITALS 113
9.5 CLINICAL TESTING LABORATORIES 114
9.6 BLOOD BANK 115
9.7 OTHERS 116
10 ASIA PACIFIC FLOW CYTOMETRY MARKET, BY DISTRIBUTION CHANNEL 117
10.1 OVERVIEW 118
10.2 RETAIL SALES 121
10.3 DIRECT TENDERS 122
11 ASIA PACIFIC FLOW CYTOMETRY MARKET, BY GEOGRAPHY 123
11.1 ASIA-PACIFIC 124
11.1.1 JAPAN 132
11.1.2 CHINA 136
11.1.3 INDIA 140
11.1.4 SOUTH KOREA 144
11.1.5 AUSTRALIA 148
11.1.6 SINGAPORE 152
11.1.7 THAILAND 156
11.1.8 MALAYSIA 160
11.1.9 INDONESIA 164
11.1.10 PHILIPPINES 168
11.1.11 REST OF ASIA-PACIFIC 172
12 ASIA PACIFIC FLOW CYTOMETRY MARKET, COMPANY LANDSCAPE 173
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 173
13 SWOT ANALYSIS 174
14 COMPANY PROFILE 175
14.1 THERMO FISHER SCIENTIFIC INC. 175
14.1.1 COMPANY SNAPSHOT 175
14.1.2 REVENUE ANALYSIS 176
14.1.3 COMPANY SHARE ANALYSIS 176
14.1.4 PRODUCT PORTFOLIO 177
14.1.5 RECENT DEVELOPMENTS 177
14.2 BD 179
14.2.1 COMPANY SNAPSHOT 179
14.2.2 REVENUE ANALYSIS 179
14.2.3 COMPANY SHARE ANALYSIS 180
14.2.4 PRODUCT PORTFOLIO 180
14.2.5 RECENT DEVELOPMENT 181
14.2.5.1 COLLABORATION 181
14.3 AGILENT TECHNOLOGIES, INC. 182
14.3.1 COMPANY SNAPSHOT 182
14.3.2 REVENUE ANALYSIS 182
14.3.3 COMPANY SHARE ANALYSIS 183
14.3.4 PRODUCT PORTFOLIO 183
14.3.5 RECENT DEVELOPMENTS 184
14.4 SARTORIUS AG 185
14.4.1 COMPANY SNAPSHOT 185
14.4.2 REVENUE ANALYSIS 185
14.4.3 COMPANY SHARE ANALYSIS 186
14.4.4 PRODUCT PORTFOLIO 186
14.4.5 RECENT DEVELOPMENT 187
14.5 NEXCELOM BIOSCIENCE LLC 188
14.5.1 COMPANY SNAPSHOT 188
14.5.2 PRODUCT PORTFOLIO 188
14.5.3 RECENT DEVELOPMENT 188
14.5.4 COMPANY SHARE ANALYSIS 189
14.6 APOGEE FLOW SYSTEMS LTD. 190
14.6.1 COMPANY SNAPSHOT 190
14.6.2 PRODUCT PORTFOLIO 190
14.6.3 RECENT DEVELOPMENT 190
14.7 BAY BIOSCIENCE CO., LTD. 191
14.7.1 COMPANY SNAPSHOT 191
14.7.2 PRODUCT PORTFOLIO 191
14.7.3 RECENT DEVELOPMENT 191
14.8 BIOMRIEUX 192
14.8.1 COMPANY SNAPSHOT 192
14.8.2 REVENUE ANALYSIS 193
14.8.3 PRODUCT PORTFOLIO 193
14.8.4 RECENT DEVELOPMENT 193
14.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER CORPORATION) 194
14.9.1 COMPANY SNAPSHOT 194
14.9.2 REVENUE ANALYSIS 194
14.9.3 PRODUCT PORTFOLIO 195
14.9.4 RECENT DEVELOPMENTS 196
14.9.4.1 ACQUISITION 196
14.9.4.2 PRODUCT LAUNCH 196
14.10 BENNUBIO INC. 198
14.10.1 COMPANY SNAPSHOT 198
14.10.2 PRODUCT PORTFOLIO 198
14.10.3 RECENT DEVELOPMENT 198
14.11 BIOLEGEND, INC. 199
14.11.1 COMPANY SNAPSHOT 199
14.11.2 PRODUCT PORTFOLIO 199
14.11.3 RECENT DEVELOPMENT 201
14.12 BIO-RAD LABORATORIES, INC. 202
14.12.1 COMPANY SNAPSHOT 202
14.12.2 REVENUE ANALYSIS 202
14.12.3 PRODUCT PORTFOLIO 203
14.12.4 RECENT DEVELOPMENT 203
14.13 CELL SIGNALING TECHNOLOGY, INC. 204
14.13.1 COMPANY SNAPSHOT 204
14.13.2 PRODUCT PORTFOLIO 204
14.13.3 RECENT DEVELOPMENT 205
14.14 CELLKRAFT BIOTECH PVT. LTD 206
14.14.1 COMPANY SNAPSHOT 206
14.14.2 PRODUCT PORTFOLIO 206
14.14.3 RECENT DEVELOPMENT 207
14.15 CYTEK BIOSCIENCES 208
14.15.1 COMPANY SNAPSHOT 208
14.15.2 PRODUCT PORTFOLIO 208
14.15.3 RECENT DEVELOPMENTS 209
14.15.3.1 PRODUCT LAUNCH 209
14.15.3.2 ACQUISITION 210
14.16 CYTOBUOY B.V. 211
14.16.1 COMPANY SNAPSHOT 211
14.16.2 PRODUCT PORTFOLIO 211
14.16.3 RECENT DEVELOPMENT 211
14.17 CYTONOME/ST, LLC 212
14.17.1 COMPANY SNAPSHOT 212
14.17.2 PRODUCT PORTFOLIO 212
14.18 COHERENT CORP. 213
14.18.1 COMPANY SNAPSHOT 213
14.18.2 REVENUE ANALYSIS 213
14.18.3 PRODUCT PORTFOLIO 214
14.18.4 RECENT DEVELOPMENTS 214
14.18.4.1 Announcement 214
14.18.4.2 PRODUCT LAUNCH 214
14.18.4.3 AWARDS 215
14.18.5 RECENT DEVELOPMENT 215
14.19 ELABSCIENCE BIOTECHNOLOGY INC. 216
14.19.1 COMPANY SNAPSHOT 216
14.19.2 PRODUCT PORTFOLIO 216
14.19.3 RECENT DEVELOPMENT 217
14.20 ENZO BIOCHEM INC. 218
14.20.1 COMPANY SNAPSHOT 218
14.20.2 REVENUE ANALYSIS 219
14.20.3 PRODUCT PORTFOLIO 219
14.20.4 RECENT DEVELOPMENT 219
14.21 IKEDA SCIENTIFIC CO., LTD. 220
14.21.1 COMPANY SNAPSHOT 220
14.21.2 PRODUCT PORTFOLIO 220
14.21.3 RECENT DEVELOPMENT 221
14.22 MERCK KGAA 222
14.22.1 COMPANY SNAPSHOT 222
14.22.2 REVENUE ANALYSIS 222
14.22.3 PRODUCT PORTFOLIO 223
14.22.4 RECENT DEVELOPMENT 223
14.23 MILTENYI BIOTEC 224
14.23.1 COMPANY SNAPSHOT 224
14.23.2 PRODUCT PORTFOLIO 224
14.23.3 RECENT DEVELOPMENT 226
14.23.3.1 PRODUCT LAUNCH 226
14.24 NANOCELLECT BIOMEDICAL 227
14.24.1 COMPANY SNAPSHOT 227
14.24.2 PRODUCT PORTFOLIO 227
14.24.3 RECENT DEVELOPMENTS 227
14.25 NEOGENOMICS LABORATORIES 229
14.25.1 COMPANY SNAPSHOT 229
14.25.2 REVENUE ANALYSIS 229
14.25.3 PRODUCT PORTFOLIO 230
14.25.4 RECENT DEVELOPMENT 230
14.26 ON-CHIP BIOTECHNOLOGIES CO., LTD. CORPORATION 231
14.26.1 COMPANY SNAPSHOT 231
14.26.2 PRODUCT PORTFOLIO 231
14.26.3 RECENT DEVELOPMENTS 231
14.27 ORFLO TECHNOLOGIES 232
14.27.1 COMPANY SNAPSHOT 232
14.27.2 PRODUCT PORTFOLIO 232
14.27.3 RECENT DEVELOPMENT 232

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.